Buy Tirzepatide 10mg in NZ for GLP-1 and weight management research.

Tirzepatide

30mg
$300.00
Skip to product information
Buy Tirzepatide 10mg in NZ for GLP-1 and weight management research.
  • Buy Tirzepatide 10mg in NZ for GLP-1 and weight management research.
  • Tirzepatide
  • Buy Tirzepatide 10mg in NZ for GLP-1 and weight management research.
  • Tirzepatide
Tirzepatide

Tirzepatide

Tirzepatide is a dual-agonist peptide studied for its potential to regulate blood glucose levels and support body weight management. It mimics the actions of both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), two hormones involved in appetite control, insulin sensitivity, and energy balance.

In research environments, Tirzepatide is being investigated for its effectiveness in studies related to weight reduction, improved glycemic control, and type 2 diabetes management.

This compound is provided for laboratory and scientific research use only in New Zealand.

Purity: ≥99.0%

Molar Mass: 4813.527 g·mol

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Sequence: H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(Eicosanedioyl-isoGlu-PEG2-PEG2)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

  1. Min, Thinzar, and Stephen C. Bain. "The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials." Diabetes Therapy 12.1 (2021): 143-157.
  2. Jastreboff, Ania M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.
  3. Frías, Juan P., et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." New England Journal of Medicine 385.6 (2021): 503-515.
  4. Syed, Yahiya Y. "Tirzepatide: first approval." Drugs 82.11 (2022): 1213-1220.
  5. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  6. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  7. Chavda, Vivek P., et al. "Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review." Molecules 27.13 (2022): 4315.

Bulk Order Discounts Available

Receive 10% off when ordering 3+ vials

Receive 15% off when ordering 6+ vials
$300.00
Content

You may also like